[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (VRTX) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM ESTCompany ParticipantsReshma Kewalramani - CEO,...",
    "url": "https://finnhub.io/api/news?id=431eaf1a2cdeb8cfe37b38b89ee00d7c81f2432ce565b0c50ef579f0d0079508",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762872091,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript",
      "id": 137450067,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (VRTX) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM ESTCompany ParticipantsReshma Kewalramani - CEO,...",
      "url": "https://finnhub.io/api/news?id=431eaf1a2cdeb8cfe37b38b89ee00d7c81f2432ce565b0c50ef579f0d0079508"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress",
    "summary": "Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...",
    "url": "https://finnhub.io/api/news?id=21b57dcbad6fe4f6f3d6b97b8d3fb3a84f1433a8fee032500d55583020429ea6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762827397,
      "headline": "The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress",
      "id": 137437880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...",
      "url": "https://finnhub.io/api/news?id=21b57dcbad6fe4f6f3d6b97b8d3fb3a84f1433a8fee032500d55583020429ea6"
    }
  }
]